Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Idioma
Tipo del documento
Intervalo de año de publicación
1.
Vopr Onkol ; 60(2): 72-9, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-24919266

RESUMEN

The study of antitumor efficacy of dioxadet in chemoperfusion treatment of ascitic ovarian cancer was carried out in 125 Wistar female rats. Ovarian cancer was inoculated intraperitoneally at a number 1x10(7) tumor cells per rat. Intraperitoneal administration of dioxadet as well as chemoperfusion was performed once in 48 hours after the ovarian cancer inoculation. Dioxadet was used at maximal tolerated doses which were 1.5 mg/kg for intraperitoneal administration, 30 mg/kg for normothermic intraperitoneal chemoperfusion (IPEC), and 15 mg/kg for hyperthermic intraperitoneal chemoperfusion (HIPEC). Antitumor effects of dioxadet were estimated in increase of median survival. In the control group, where animals didn't receive any treatment, the median survival was 9 days. Increase of the median survival after intraperitoneal administration of dioxadet, IPEC and HIPEC with dioxadet was 211% (p=0,001), 244% (p=0,001) and 444% (p=0,001), respectively, compared to the control group. Hence, intraperitoneal chemoperfusion with dioxadet (normo- or hyperthermic) is more effective compared to standard intraperitoneal administration of the drug. At HIPEC with dioxadet potentiating antitumor action of hyperthermia and dioxadet on the ovarian cancer growth was achieved.


Asunto(s)
Antineoplásicos/administración & dosificación , Antineoplásicos/farmacología , Quimioterapia del Cáncer por Perfusión Regional , Hipertermia Inducida , Neoplasias Ováricas/tratamiento farmacológico , Triazinas/administración & dosificación , Triazinas/farmacología , Animales , Quimioterapia del Cáncer por Perfusión Regional/métodos , Femenino , Infusiones Parenterales , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Ováricas/patología , Ratas , Ratas Wistar , Análisis de Supervivencia , Resultado del Tratamiento
2.
Vopr Onkol ; 60(1): 71-9, 2014.
Artículo en Ruso | MEDLINE | ID: mdl-24772620

RESUMEN

An experimental technology of normothermic intraperitoneal chemoperfusion and hyperthermic intraperitoneal chemoperfusion with cisplatin and dioxadet has been elaborated to treat abdominal carcinomatosis in ovarian cancer. Antitumor effects of the treatment were evaluated for the duration of animal life. Normothermic intraperitoneal chemoperfusion and hyperthermic intraperitoneal chemoperfusion with cisplatin and dioxadet in comparison with the standard intraperitoneal administration significantly increased the median life expectancy by 75-92%. Hyperthermic intraperitoneal chemoperfusion with dioxadet demonstrated potentiation of antitumor effect of hyperthermia and dioxadet. Experimental technology is recommended for testing new drugs and methods of chemoperfusion for malignant tumors affecting the peritoneum.


Asunto(s)
Neoplasias Abdominales/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Carcinoma/tratamiento farmacológico , Quimioterapia del Cáncer por Perfusión Regional/instrumentación , Hipertermia Inducida , Neoplasias Ováricas/tratamiento farmacológico , Neoplasias Abdominales/secundario , Animales , Carcinoma/secundario , Quimioterapia del Cáncer por Perfusión Regional/métodos , Cisplatino/administración & dosificación , Femenino , Neoplasias Experimentales/tratamiento farmacológico , Neoplasias Ováricas/patología , Pelvis , Ratas , Ratas Wistar , Triazinas/administración & dosificación
3.
Radiobiologiia ; 32(4): 493-9, 1992.
Artículo en Ruso | MEDLINE | ID: mdl-1410284

RESUMEN

A study was made of some embryological, hematological, cytogenetic and biochemical characteristics in Wistar rats exposed within the Chernobyl NPP zone over a period of 30 days (the average radiation background level, 75, and at the soil surface, 115 mR/h; a cumulative dose, 57 rad/30 days, and for pregnant rats, 36 rad/20 days). The quantity of chromosome aberrations in bone marrow metaphases and the embryonal death rate were invariable; some cases of teratogenesis were, however, observed. The total number of karyocytes in the brain and the leukocyte content in the peripheral blood sometimes decreased. The changes in certain characteristics (such as the content of endogenous amines and thiols in the liver and spleen) of the endogenous radioresistance background (ERB) and the normalization of the ERB by the radioprotective agent MIGI-K were found.


Asunto(s)
Accidentes , Contaminantes Radiactivos del Aire/efectos adversos , Reactores Nucleares , Centrales Eléctricas , Traumatismos Experimentales por Radiación/tratamiento farmacológico , Protectores contra Radiación/uso terapéutico , Animales , Relación Dosis-Respuesta en la Radiación , Evaluación Preclínica de Medicamentos , Femenino , Masculino , Traumatismos Experimentales por Radiación/metabolismo , Traumatismos Experimentales por Radiación/patología , Ratas , Ratas Wistar , Ucrania
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA